An Open Label Prospective Clinical Study to evaluate the effects of N-163 strain of Aureobasidium Pullulans Produced Î² 1,3-16 Glucans in modulating the immunity in patients with Psoriasis

ichi-In Bio Sciences Pvt. Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年6月26日

研究概览

暂无简介。

•1. Males and females at least 18 years of age.
•2. Except for plaque psoriasis with or without arthritis, subject is in generally good health.
•3. Subject exhibits acutely active at least moderate to severe plaque-type psoriasis ( > 5% body surface area (BSA) involvement).
•4. Signed, written informed consent
•5. Willing and able to comply with study visits according to protocol for the full study period

•1. Patients with forms of psoriasis other than chronic plaque-type psoriasis or with drug-induced psoriasis
•2. Use of an investigational drug within 90 days prior to Day 1.
•3. Patients suffering from significant cardiac, renal or hepatic failure or any other disease that may risk the patient or interfere with the ability to interpret the results
•4. Patient with any active or chronic infection
•5. Pregnancy or risk of pregnancy.
•6. Patients who are seropositive for HIV1, HIV2, Hepatitis B Surface Antigen, and Hepatitis C
•7. Patients unable to give written informed consent

发起方

ichi-In Bio Sciences Pvt. Ltd